biotech / news / / manilastandard.net
Novo Nordisk, the pharmaceutical company behind Ozempic, launched an obesity awareness campaign.
Novo Nordisk officially introduced Wegovy, a weight management drug, to the Philippines last Friday.
KEY POINTS
- Obesity costs in the Philippines are projected to reach Php 1.9 trillion in 2025, or 7.3% of GDP.
- Wegovy is based on semaglutide, a GLP-1 receptor agonist targeting appetite and metabolic processes.
- Wegovy is not recommended for those with certain thyroid cancers or hypersensitivity to semaglutide.
COMPANIES
Summarized by Newsio from manilastandard.net. How we summarize →